Swedish Orphan Biovitrum AB(SE:SOBI)
kr 474.20-12.80 (-2.63%)
SE:SOBI
Swedish Orphan Biovitrum AB stock drug pipeline
kr 474.20
At close:-12.80 (-2.63%)
Want to see SE:SOBI full AI Analyst Report?
Swedish Orphan Biovitrum AB (SOBI) Drug Pipeline
8 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Efanesoctocog Alfa | Hemophilia A | Phase IV | Recruiting | Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa | Apr 16, 2025 | ― |
| Pacritinib | Vexas, Vexas Syndrome | Phase II | Recruiting | A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) | Jan 07, 2025 | ― |
| Efanesoctocog Alfa | Hemophilia, Haemophilia A (Moderate Or Severe), Hemophilia, Classic, Haemophilia, Classic Hemophilia, Synovial Hypertrophy | Phase IV | Recruiting | A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis | Dec 18, 2024 | ― |
| Anakinra | Familial Mediterranean Fever (Fmf ) | Phase IV | Not Yet Recruiting | A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF | Oct 08, 2024 | ― |
| Efanesoctocog Alfa | Severe Haemophilia A | Phase III | Recruiting | Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa | Oct 02, 2024 | ― |
| Efanesoctocog Alfa | Hemophilia A | Phase I | Recruiting | Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A | Aug 28, 2024 | ― |
| Haemophilia Early Arthropathy Detection With Ultrasound (Head-Us), Haemophilia Joint Health Score (Hjhs) | Hemophilia B, Hemophilia A | Phase IV | Terminated | An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa | Apr 24, 2023 | ― |
| Efanesoctocog Alfa | Hemophilia A, Severe | Phase III | Active Not Recruiting | A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa | Mar 21, 2023 | ― |
| Emapalumab-Lzsg 5 Mg/Ml [Gamifant] | Primary Hemophagocytic Lymphohistiocytosis | Phase IV | Completed | A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients | Feb 13, 2023 | ― |
| Anakinra | Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset | Phase III | Active Not Recruiting | A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD) | Nov 22, 2022 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Efanesoctocog Alfa | Phase IV | Hemophilia A | Recruiting | Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa | Apr 16, 2025 | ― |
| Pacritinib | Phase II | Vexas, Vexas Syndrome | Recruiting | A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) | Jan 07, 2025 | ― |
| Efanesoctocog Alfa | Phase IV | Hemophilia, Haemophilia A (Moderate Or Severe), Hemophilia, Classic, Haemophilia, Classic Hemophilia, Synovial Hypertrophy | Recruiting | A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis | Dec 18, 2024 | ― |
| Anakinra | Phase IV | Familial Mediterranean Fever (Fmf ) | Not Yet Recruiting | A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF | Oct 08, 2024 | ― |
| Efanesoctocog Alfa | Phase III | Severe Haemophilia A | Recruiting | Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa | Oct 02, 2024 | ― |
| Efanesoctocog Alfa | Phase I | Hemophilia A | Recruiting | Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A | Aug 28, 2024 | ― |
| Haemophilia Early Arthropathy Detection With Ultrasound (Head-Us), Haemophilia Joint Health Score (Hjhs) | Phase IV | Hemophilia B, Hemophilia A | Terminated | An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa | Apr 24, 2023 | ― |
| Efanesoctocog Alfa | Phase III | Hemophilia A, Severe | Active Not Recruiting | A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa | Mar 21, 2023 | ― |
| Emapalumab-Lzsg 5 Mg/Ml [Gamifant] | Phase IV | Primary Hemophagocytic Lymphohistiocytosis | Completed | A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients | Feb 13, 2023 | ― |
| Anakinra | Phase III | Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset | Active Not Recruiting | A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD) | Nov 22, 2022 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Swedish Orphan Biovitrum Ab (SE:SOBI) have in its pipeline
Swedish Orphan Biovitrum AB SE:SOBI is currently developing the following drugs: Efanesoctocog Alfa, Pacritinib, Anakinra, Haemophilia Early Arthropathy Detection With Ultrasound (Head-Us), Haemophilia Joint Health Score (Hjhs), Emapalumab-Lzsg 5 Mg/Ml [Gamifant], Pegcetacoplan, Emapalumab, Normal Saline, Sel-212 Low-Dose, Sel-212 High-Dose, Pacritinib, Physician's Choice Medications. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
